Joint Accreditation Statement
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number:
JA4008162-9999-19-805-L01-P; Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Hardware/Software Requirements
The webinar is accessed through GoToWebinar. An internet connection and the system requirements are needed to access the webinar.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Educational Objectives
Upon completion of this program, participants will be able to:
- Describe the current guidelines for implementing cancer immunotherapy into practice based on the latest approvals and technologies available in the field
- Identify how to incorporate cancer immunotherapy into clinical practice according to the SITC guidelines
- Implement cancer immunotherapy treatments according to the SITC cancer immunotherapy guidelines
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
This webinar is supported, in part, by independent medical education grant funding from Amgen and AstraZeneca Pharmaceuticals LP